👉 In biotech, it is widely assumed that strong data naturally leads to strong execution . If experiments are rigorous and results are validated, progress should be inevitable. This belief is deeply embedded in scientific culture, and it feels rational. Yet in reality, biotech execution rarely breaks because of weak data . It breaks because teams avoid making hard choices. More precisely, they avoid explicitly acknowledging the tradeoffs that shape every execution path . 👉 F

Most biotech founders do not fail because the science is weak. 👉 They struggle because the questions change before they feel ready to answer them. You walk into an investor meeting expecting to defend your data. You walk out, realizing they were evaluating something else entirely. Not later. Now. A quiet shift is happening in biotech fundraising. It is not louder term sheets or harsher investors. It is timing.  Questions that used to come after progress now arrive before com

👉 Most biotech founders believe in collaboration in biotech. They value smart teams, open discussion, and shared ownership. Yet many still feel that decisions drift, priorities blur, and momentum slows.  This is confusing because the intent is there. The effort is real. 👉 Something still does not connect. The issue is rarely a lack of talent or trust. In most early-stage biotech teams, people are committed and capable. The real tension appears elsewhere. 👉 Science and stra